Publications

Christopher Johns, Hala Borno, Samuel L. Washington, Wesley Robinson, Miriam Perales, Rahul Raj Aggarwal, Rohit Bose, Jonathan Chou, Arpita Desai, Kelly N. Fitzgerald, Terence W. Friedlander, Vadim S Koshkin, Ivan de Kouchkovsky, Elizabeth Pan, Eric J. Small, Noah Spector Younger, Xiaolin Zhu, Franklin W. Huang, Daniel H. Kwon. Development of a culturally tailored educational tool designed to increase access to somatic testing among Black men with metastatic prostate cancer (mPCa). Journal of Clinical Oncology. 2025. PMID:


Hala Borno, MD

Tanya Jindal, Emily Wu, Sara Topalovic, Nana Shakhnazaryan, Sylvia Zhang, Hala Borno. Enhancing clinical trial site efficiency and unlocking patient access to clinical trials using technology-enabled pre-screening. Journal of Clinical Oncology. 2025. PMID:


Hala Borno, MD

Pan D, Kumar A, Lipof JJ, Chung A, Wolf JL, Martin TG, Arora S, Sayre PH, Chari A. Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review. Expert opinion on investigational drugs. 2025. PMID: 40425184


Alfred Chung, MD

Pan D, Kumar A, Lipof JJ, Chung A, Wolf JL, Martin TG, Arora S, Sayre PH, Chari A. Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review. Expert opinion on investigational drugs. 2025. PMID: 40425184


Ajai Chari, MD

Pan D, Kumar A, Lipof JJ, Chung A, Wolf JL, Martin TG, Arora S, Sayre PH, Chari A. Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review. Expert opinion on investigational drugs. 2025. PMID: 40425184


Darren Pan, MD

Pan D, Kumar A, Lipof JJ, Chung A, Wolf JL, Martin TG, Arora S, Sayre PH, Chari A. Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review. Expert opinion on investigational drugs. 2025. PMID: 40425184


Jodi Lipof, MD

Pan D, Kumar A, Lipof JJ, Chung A, Wolf JL, Martin TG, Arora S, Sayre PH, Chari A. Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review. Expert opinion on investigational drugs. 2025. PMID: 40425184


Peter Sayre, MD, PhD

Pan D, Kumar A, Lipof JJ, Chung A, Wolf JL, Martin TG, Arora S, Sayre PH, Chari A. Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review. Expert opinion on investigational drugs. 2025. PMID: 40425184


Thomas Martin, MD

Pan D, Kumar A, Lipof JJ, Chung A, Wolf JL, Martin TG, Arora S, Sayre PH, Chari A. Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review. Expert opinion on investigational drugs. 2025. PMID: 40425184


Jeffrey Wolf, MD

Kawasaki K, Salehi S, Zhan YA, Chen K, Lee JH, Salataj E, Zhong H, Manoj P, Kinyua D, Mello BP, Sridhar H, Tischfield SE, Linkov I, Ceglia N, Zatzman M, Havasov E, Shah NJ, Meng F, Loomis B, Bhanot UK, Redin E, de Stanchina E, Hamard PJ, Koche RP, McPherson A, Quintanal-Villalonga Á, Shah SP, Massagué J, Rudin CM. FOXA2 promotes metastatic competence in small cell lung cancer. Nature communications. 2025. PMID: 40419484


Neil Pravin Shah, MD

Menzies AM, Long GV, Kohn A, Tawbi H, Webe J, Flaherty K, McArthur GA, Ascierto PA, Pfluger Y, Lewis K, Tsai KK, Hamid O, Prenen H, Fein L, Wang E, Guenzel C, Zhang F, Kleh JF, di Pietro A, Davies MA. A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis. Future oncology (London, England). 2025. PMID: 40418081


Katy Tsai, MD

Stinchcombe TE, Fleming GF, Craddock C, Ko AH, O'Reilly EM, Maki RG. Early-Phase Trials in Journal of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40403204


Andrew Ko, MD

St-Laurent MP, Singh P, McConkey DJ, Lucia MS, Koshkin VS, Stratton KL, Bivalacqua TJ, Kassouf W, Porten SP, Bangs R, Plets M, Thompson IM, Meeks JJ, Caruso VM, Ward CT, Mazzarella BC, Phillips KG, Bicocca VT, Levin TG, Lerner SP, Black PC. Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer. European urology. 2025. PMID: 40404526


Vadim Koshkin, MD

Hillege LE, Trepka KR, Guthrie BGH, Fu X, Aarnoutse R, Paymar MR, Olson C, Zhang C, Ortega E, Ramirez L, de Vos-Geelen J, Valkenburg-van Iersel L, van Hellemond IEG, Baars A, Vestjens JHMJ, Penders J, Deutschbauer A, Atreya CE, Kidder WA, Smidt ML, Ziemons J, Turnbaugh PJ. Microbial vitamin biosynthesis links gut microbiota dynamics to chemotherapy toxicity. mBio. 2025. PMID: 40391895


Chloe Atreya, MD, PhD

Hillege LE, Trepka KR, Guthrie BGH, Fu X, Aarnoutse R, Paymar MR, Olson C, Zhang C, Ortega E, Ramirez L, de Vos-Geelen J, Valkenburg-van Iersel L, van Hellemond IEG, Baars A, Vestjens JHMJ, Penders J, Deutschbauer A, Atreya CE, Kidder WA, Smidt ML, Ziemons J, Turnbaugh PJ. Microbial vitamin biosynthesis links gut microbiota dynamics to chemotherapy toxicity. mBio. 2025. PMID: 40391895


Wes Kidder, MD, MPH

Bierer SB, Beck Dallaghan G, Borges NJ, Brondfield S, Fung CC, Huggett KN, Teal CR, Thammasitboon S, Colbert CY. Moving Beyond Simplistic Research Design in Health Professions Education: What a One-Group Pretest-Posttest Design Will Not Prove. MedEdPORTAL : the journal of teaching and learning resources. 2025. PMID: 40395408


Sam Brondfield, MD

Lau G, Sangro B, Cheng AL, Kudo M, Kelley RK, Tak WY, Gasbarrini A, Reig M, Lim HY, Tougeron D, De Toni EN, Tam VC, Mody K, Gong J, Crysler OV, Sukeepaisarnjaroen W, Lipatov O, Morimoto M, Archambeaud I, Burgio V, Phuong LTT, Chao Y, Peron JM, Berres ML, Ko YJ, Ran D, Makowsky M, Negro A, Abou-Alfa GK. Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial. Hepatology (Baltimore, Md.). 2025. PMID: 40384092


Robin Kate ("Katie") Kelley, MD

Corti C, Rugo HS, Tolaney SM. Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2025. PMID: 40367401


Hope Rugo, MD

Kasap C, Izgutdina A, Patiño-Escobar B, Kang AS, Chilakapati N, Akagi N, Manoj AM, Johnson H, Rashid T, Werner J, Barpanda A, Geng H, Lin YT, Rampersaud S, Gil-Alós D, Sobh A, Dupéré-Richer D, Aleman A, Wicaksono G, Kelii KMK, Dalal R, Ramos E, Vijayanarayanan A, Lakhani K, Salangsang F, Phojanakong P, Camara Serrano JA, Zakraoui O, Tariq I, Chari A, Chung A, Kumar AD, Martin T, Wolf JL, Wong S, Steri V, Shanmugam M, Boise LH, Kortemme T, Parekh S, Stieglitz E, Licht JD, Karlon W, Barwick BG, Wiita A. Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells. Blood. 2025. PMID: 40359480


Jeffrey Wolf, MD

Kasap C, Izgutdina A, Patiño-Escobar B, Kang AS, Chilakapati N, Akagi N, Manoj AM, Johnson H, Rashid T, Werner J, Barpanda A, Geng H, Lin YT, Rampersaud S, Gil-Alós D, Sobh A, Dupéré-Richer D, Aleman A, Wicaksono G, Kelii KMK, Dalal R, Ramos E, Vijayanarayanan A, Lakhani K, Salangsang F, Phojanakong P, Camara Serrano JA, Zakraoui O, Tariq I, Chari A, Chung A, Kumar AD, Martin T, Wolf JL, Wong S, Steri V, Shanmugam M, Boise LH, Kortemme T, Parekh S, Stieglitz E, Licht JD, Karlon W, Barwick BG, Wiita A. Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells. Blood. 2025. PMID: 40359480


Alfred Chung, MD